Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent

Hype or reality?

Mehmet Kanbay, Yalcin Solak, Abduzhappar Gaipov, Mumtaz Takir, Daniel E. Weiner

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Numerous experimental and clinical studies suggest that uric acid might have pathobiologic implications in the development and progression of hypertension, kidney disease, and coronary heart disease, among others, resulting in renewed interest in uric acid as a potential pathogenic mediator in these clinical conditions. Despite encouraging animal studies showing beneficial roles of allopurinol, clinical studies and randomized controlled trials remain scarce, and, despite available clinical evidence supporting a therapeutic role for allopurinol, multiple issues remain before routine use of allopurinol can be recommended for use in patients with hyperuricemia and hypertension, kidney disease, or coronary heart disease. These include a need for more robust clinical trial data that evaluate efficacy on hard clinical outcomes, optimal dose, duration of treatment, and the potential for serious allergic reactions. In this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.

Original languageEnglish (US)
Pages (from-to)172-178
Number of pages7
JournalBlood Purification
Volume37
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Cardiotonic Agents
Protective Agents
Allopurinol
Antihypertensive Agents
Kidney
Kidney Diseases
Uric Acid
Coronary Disease
Hypertension
Hyperuricemia
Gout
Hypersensitivity
Randomized Controlled Trials
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent : Hype or reality? / Kanbay, Mehmet; Solak, Yalcin; Gaipov, Abduzhappar; Takir, Mumtaz; Weiner, Daniel E.

In: Blood Purification, Vol. 37, No. 3, 01.01.2014, p. 172-178.

Research output: Contribution to journalReview article

Kanbay, Mehmet ; Solak, Yalcin ; Gaipov, Abduzhappar ; Takir, Mumtaz ; Weiner, Daniel E. / Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent : Hype or reality?. In: Blood Purification. 2014 ; Vol. 37, No. 3. pp. 172-178.
@article{9e5fa0746df14350b209e4691e4c9d88,
title = "Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent: Hype or reality?",
abstract = "Numerous experimental and clinical studies suggest that uric acid might have pathobiologic implications in the development and progression of hypertension, kidney disease, and coronary heart disease, among others, resulting in renewed interest in uric acid as a potential pathogenic mediator in these clinical conditions. Despite encouraging animal studies showing beneficial roles of allopurinol, clinical studies and randomized controlled trials remain scarce, and, despite available clinical evidence supporting a therapeutic role for allopurinol, multiple issues remain before routine use of allopurinol can be recommended for use in patients with hyperuricemia and hypertension, kidney disease, or coronary heart disease. These include a need for more robust clinical trial data that evaluate efficacy on hard clinical outcomes, optimal dose, duration of treatment, and the potential for serious allergic reactions. In this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.",
author = "Mehmet Kanbay and Yalcin Solak and Abduzhappar Gaipov and Mumtaz Takir and Weiner, {Daniel E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000360520",
language = "English (US)",
volume = "37",
pages = "172--178",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent

T2 - Hype or reality?

AU - Kanbay, Mehmet

AU - Solak, Yalcin

AU - Gaipov, Abduzhappar

AU - Takir, Mumtaz

AU - Weiner, Daniel E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Numerous experimental and clinical studies suggest that uric acid might have pathobiologic implications in the development and progression of hypertension, kidney disease, and coronary heart disease, among others, resulting in renewed interest in uric acid as a potential pathogenic mediator in these clinical conditions. Despite encouraging animal studies showing beneficial roles of allopurinol, clinical studies and randomized controlled trials remain scarce, and, despite available clinical evidence supporting a therapeutic role for allopurinol, multiple issues remain before routine use of allopurinol can be recommended for use in patients with hyperuricemia and hypertension, kidney disease, or coronary heart disease. These include a need for more robust clinical trial data that evaluate efficacy on hard clinical outcomes, optimal dose, duration of treatment, and the potential for serious allergic reactions. In this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.

AB - Numerous experimental and clinical studies suggest that uric acid might have pathobiologic implications in the development and progression of hypertension, kidney disease, and coronary heart disease, among others, resulting in renewed interest in uric acid as a potential pathogenic mediator in these clinical conditions. Despite encouraging animal studies showing beneficial roles of allopurinol, clinical studies and randomized controlled trials remain scarce, and, despite available clinical evidence supporting a therapeutic role for allopurinol, multiple issues remain before routine use of allopurinol can be recommended for use in patients with hyperuricemia and hypertension, kidney disease, or coronary heart disease. These include a need for more robust clinical trial data that evaluate efficacy on hard clinical outcomes, optimal dose, duration of treatment, and the potential for serious allergic reactions. In this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.

UR - http://www.scopus.com/inward/record.url?scp=84901738522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901738522&partnerID=8YFLogxK

U2 - 10.1159/000360520

DO - 10.1159/000360520

M3 - Review article

VL - 37

SP - 172

EP - 178

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 3

ER -